See more : China Industrial Waste Management, Inc. (CIWT) Income Statement Analysis – Financial Results
Complete financial analysis of Applied Genetic Technologies Corporation (AGTC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Applied Genetic Technologies Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- China Aluminum International Engineering Corporation Limited (2068.HK) Income Statement Analysis – Financial Results
- Boston Scientific Corporation (0HOY.L) Income Statement Analysis – Financial Results
- Chaarat Gold Holdings Limited (CGH.L) Income Statement Analysis – Financial Results
- Praram 9 Hospital Public Company Limited (PR9.BK) Income Statement Analysis – Financial Results
- Cairo Communication S.p.A. (0N7I.L) Income Statement Analysis – Financial Results
Applied Genetic Technologies Corporation (AGTC)
About Applied Genetic Technologies Corporation
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 325.00K | 500.00K | 2.45M | 41.69M | 24.19M | 39.47M | 47.36M | 2.35M | 1.13M | 942.00K | 1.08M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 325.00K | 500.00K | 2.45M | 41.69M | 24.19M | 39.47M | 47.36M | 2.35M | 1.13M | 942.00K | 1.08M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 49.52M | 44.40M | 35.78M | 33.18M | 32.18M | 26.22M | 38.86M | 16.53M | 8.50M | 3.13M | 2.35M |
| General & Administrative | 16.99M | 14.55M | 13.62M | 12.86M | 14.39M | 11.35M | 10.59M | 10.36M | 5.18M | 1.40M | 787.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.99M | 14.55M | 13.62M | 12.86M | 14.39M | 11.35M | 10.59M | 10.36M | 5.18M | 1.40M | 787.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 66.50M | 58.95M | 49.40M | 46.04M | 46.57M | 37.57M | 49.45M | 26.89M | 13.69M | 4.54M | 3.14M |
| Cost & Expenses | 66.50M | 58.95M | 49.40M | 46.04M | 46.57M | 37.57M | 49.45M | 26.89M | 13.69M | 4.54M | 3.14M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 42.00K | 0.00 | 0.00 |
| Interest Expense | 2.67M | 1.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 191.00K | 69.00K |
| Depreciation & Amortization | 1.51M | 1.46M | 1.34M | 1.27M | 1.18M | 912.00K | 567.00K | 376.00K | 334.00K | 285.00K | 262.00K |
| EBITDA | -64.76M | -56.97M | -46.94M | -4.35M | -20.05M | 3.72M | -814.00K | -24.53M | -12.56M | -4.51M | -1.59M |
| EBITDA Ratio | -19,925.23% | -11,394.20% | -1,813.05% | -1.58% | -82.91% | 9.42% | -1.72% | -1,017.08% | -1,379.45% | -479.19% | -147.23% |
| Operating Income | -66.27M | -58.45M | -46.94M | -4.35M | -22.38M | 1.90M | -2.09M | -24.53M | -12.56M | -3.59M | -2.06M |
| Operating Income Ratio | -20,390.46% | -11,690.20% | -1,913.66% | -10.43% | -92.55% | 4.82% | -4.41% | -1,042.14% | -1,112.13% | -381.53% | -190.30% |
| Total Other Income/Expenses | -2.58M | -1.39M | 1.18M | 2.46M | 1.18M | 905.00K | 708.00K | 214.00K | -3.35M | -1.40M | 135.00K |
| Income Before Tax | -68.75M | -59.84M | -45.76M | -1.90M | -21.21M | 2.81M | -1.38M | -24.32M | -15.91M | -4.99M | -1.92M |
| Income Before Tax Ratio | -21,153.85% | -11,968.20% | -1,865.55% | -4.55% | -87.69% | 7.11% | -2.92% | -1,033.05% | -1,409.03% | -529.72% | -177.82% |
| Income Tax Expense | 2.67M | -2.11M | 83.00K | 76.00K | 72.00K | 2.40M | 708.00K | 214.00K | -3.35M | -1.21M | 204.00K |
| Net Income | -71.42M | -57.83M | -45.89M | -2.01M | -21.30M | 407.00K | -1.38M | -24.32M | -15.91M | -4.99M | -1.92M |
| Net Income Ratio | -21,976.62% | -11,565.80% | -1,870.85% | -4.81% | -88.07% | 1.03% | -2.92% | -1,033.05% | -1,409.03% | -529.72% | -177.82% |
| EPS | -1.59 | -1.77 | -2.17 | -0.11 | -1.18 | 0.02 | -0.08 | -1.50 | -4.46 | -1.20 | -0.28 |
| EPS Diluted | -1.59 | -1.77 | -2.17 | -0.11 | -1.18 | 0.02 | -0.08 | -1.50 | -4.46 | -1.20 | -0.28 |
| Weighted Avg Shares Out | 45.03M | 32.76M | 21.10M | 18.16M | 18.11M | 18.07M | 17.81M | 16.25M | 3.57M | 4.15M | 6.89M |
| Weighted Avg Shares Out (Dil) | 45.03M | 32.76M | 21.10M | 18.16M | 18.11M | 18.39M | 17.81M | 16.25M | 3.57M | 4.15M | 6.89M |
AGTC Announces Two Key Leadership Team Appointments
- AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sarah C. DiSalvatore as the Vice President of Clinical Operations - - AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sarah C. DiSalvatore as the Vice President...
AGTC to Present at Upcoming Cell & Gene Meeting on the Mesa
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced Sue...
AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today...
Kids Suffer Adverse Reactions In Applied Genetic's Color Blindness Gene Therapy Trial
After escalating the dose in its pediatric gene therapy trial, Applied Genetic Technologies Corporation (NASDAQ: AGTC) has run into safety problems. The Company recently enrolled six pediatric achromatopsia (ACHM) with CNGB3 gene mutation and five pediatric ACHM patients with CNGA3 mutation in...
Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2021 Results - Earnings Call Transcript
Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2021 Results - Earnings Call Transcript
AGTC Provides Financial Results for the Fourth Quarter and Year Ended June 30, 2021
-Data from ongoing clinical trials in XLRP and ACHM shows evidence of clinical activity and tolerability; multiple data readouts expected in 2021 and 2022-
AGTC to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management...
AGTC to Present at the 2021 Wells Fargo Virtual Healthcare Conference
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management...
Greater Gift, AGTC, and 2020 On-site Partner To Honor & Celebrate Clinical Trial Participants and Provide Eye Exams to Underserved Children in the Local Community
WINSTON SALEM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Greater Gift of Winston Salem, a non-profit that celebrates participation in clinical trials today announced a partnership with Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company developing genetic therapies for...
AGTC Announces Sponsorship of Achroma Corp's No Roadblocks Program
- Program helps those living with Achromatopsia receive filtered glasses and contact lenses to qualify for bioptic driving-
Source: https://incomestatements.info
Category: Stock Reports